3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
498
Rectal Neoplasms
268
Colonic Neoplasms
219
Pancreatic Neoplasms
190
Stomach Neoplasms
183
Esophageal Neoplasms
135
Neoplasm Metastasis
98
Adenocarcinoma Of Esophagus
67
Esophageal Squamous Cell Carcinoma
62
Carcinoma, Hepatocellular
56
Neoplasms
44
Cholangiocarcinoma
33
Biliary Tract Neoplasms
27
Adenocarcinoma
27
Anus Neoplasms
26
Gastrointestinal Neoplasms
25
Gallbladder Neoplasms
22
Liver Neoplasms
21
Carcinoma, Non-Small-Cell Lung
20
Bile Duct Neoplasms
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
16
Ovarian Neoplasms
11
Digestive System Neoplasms
10
Colorectal Cancer Metastatic
10
Carcinoma, Squamous Cell
10
Peritoneal Neoplasms
9
Breast Neoplasms
9
Anal Canal Carcinoma
9
Lung Neoplasms
8
Head and Neck Neoplasms
8
Interventions
camrelizumab
2
apatinib
2
Ramucirumab
2
trifluridine tipiracil drug combination
1
tipiracil
1
irinotecan sucrosofate
1
Trifluridine
1
S 1 (combination)
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Gastric Adenocarcinoma
×
Fluorouracil
×
Gastrointestinal
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts